Gut Microbiota Differ in Men With Prostate Cancer
|
By LabMedica International staff writers Posted on 06 Jul 2022 |

Gut microbiota are the collection of microbes in the gastrointestinal tract and they affect processes and mechanisms in the body. The state of gut microbiota has been linked to many conditions, even in organs that are far from the intestines, but their role in prostate cancer is not understood.
Prostate cancer is the most common male cancer globally, but varying rates in different parts of the world are little understood. It is common in most Western countries and less common elsewhere. Though it is known to be hereditary, there is evidence that men who emigrated from low to high incidence areas have increased risk of prostate cancer in their lifetimes, and their offspring have the risk of the high incidence region.
Clinical Urologists at theUniver sity of Turku (Turku, Finland) and their colleagues used samples collected from patients on a prospective multi-center clinical study. They sequenced the gut microbiota of 181 men who were suspected to have prostate cancer and undergoing prostate cancer diagnostics. The microbiota samples were collected at the time of their prostate biopsies after MRI scans.
The investigators reported that 60% of the men were diagnosed with prostate cancer, and their gut microbiota profiles were significantly different to those who had benign biopsies. The men with cancer had increased levels of Prevotella 9, members of the family Erysipelotrichaceae, and Escherichia-Shigella, a pathogen that causes diarrhea. They also had lower levels of Jonquetella, Moryella, Anaeroglobus, Corynebacterium and Clostridium sp., CAG-352 than men who had no cancer.
Peter Bostrom, MD, PhD, a Professor of Urology and lead author of the study, said, “There are significant variations in prostate cancer rates around the world, which could be due to genetic factors or differences in healthcare policies, but also variance in lifestyle and diet. The difference in gut microbiota between men with and without prostate cancer could underpin some of these variations. More studies are needed to look at the potential for using gut microbiota for both diagnostic and preventive strategies.” The study was presented at the European Association of Urology annual congress held July 1-4, 2022, in Amsterdam, the Netherlands.
Related Links:
University of Turku
Latest Microbiology News
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
Channels
Clinical Chemistry
view channel
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read more
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read moreMolecular Diagnostics
view channel
Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
Delays in obtaining molecular test results can hinder timely oncology decisions and widen disparities for patients far from centralized laboratories. Prolonged waits may also heighten anxiety and increase... Read more
New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
Prenatal genetic screening often requires multiple tests, blood draws, and follow-up appointments, delaying access to clinically relevant information. Early, consolidated insights may help clinicians coordinate... Read more
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreHematology
view channel
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more








